Last edition
News about "TAZVERIK"
Ipsen Discontinues Tazverik for Certain Cancer Uses
In addition to withdrawing Tazverik from the market, Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the ongoing SYMPHONY-1 trial. All participants will receive standard of care, lenalidomide plus rituximab only.
Tazverik | 09/03/2026 | By News Bureau | 144
HUTCHMED Gains Wider NRDL Coverage and First Commercial Insurance Listing in China
Effective January 1, 2026, HUTCHMED will see expanded NRDL coverage for ELUNATE, ORPATHYS and SULANDA, while TAZVERIK has been added to China’s first National Commercial Health Insurance Innovative Drug List, marking its entry into commercial insurance coverage.
TAZVERIK | 08/12/2025 | By Dineshwori | 185
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy